AmpliPhi Biosciencess C3J Logo

Armata has joined together two seasoned drug development teams, AmpliPhi Biosciences and C3J Therapeutics, to tackle the global and increasingly serious threat of antimicrobial-resistant bacterial infections. Driven by rigorous and innovative science, Armata is developing high-impact, best-in-class bacteriophage therapeutics with the potential to save millions of lives.

Armata Pharmaceuticals
Enter

AP-SA01

Natural Phage Product Candidate for Staphylococcus aureus Infections

Armata’s lead product candidate, AP-SA01 (previously referred to as AB-SA01), targets Staphylococcus aureus. This investigational therapeutic is produced using our proprietary phage-specific GMP manufacturing capabilities. The 3 natural phage that comprise the product candidate were chosen for their ability to cover approximately 95% of S. aureus clinical isolates, including multidrug-resistant strains. Human exposure obtained from two previously completed Phase 1 studies and through use under investigator Emergency IND, indicate that AP-SA01 is generally well-tolerated. AP-SA01 is poised to enter formal randomized clinical trials in S. aureus bacteremia.

The Centers for Disease Control and Prevention estimates that 1.5 million people in the U.S. develop bacteremia each year and approximately 250,000 deaths occur as a direct result of infection. It is estimated that one in three patients who die in the hospital have bacteremia. Bacteremia is the most expensive condition treated at U.S. hospitals, costing approximately $24 billion annually.  S. aureus is the second most common pathogen associated with bacteremia, causing approximately 150,000 cases each year that lead to approximately 30,000 deaths.